Seres Therapeutics reported a net income of $4.6 million for Q2 2026, driven by a $25 million gain from the Nestlé VOWST milestone termination payment. The company holds $15.6 million in cash and projects operations funded through Q1 2027. Clinical updates highlighted that 80% of SER-155 recipients achieved immunosuppressive-free response for irEC, prompting partner engagement. Seres also terminated its Sidney Street lease to reduce costs and recorded a $5.8 million impairment charge. The company operates in the biotechnology industry, developing live biotherapeutics.

Seres Therapeutics entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC on July 31, 2026, to terminate its lease for approximately 21,295 square feet of space at 200 Sidney Street in Cambridge, Massachusetts. The agreement reduces annual facilities costs by surrendering the Early Termination Premises effective August 1, 2026, and shortens the remaining term for the Renewal Premises to December 31, 2026. Consideration includes increasing a letter of credit by approximately $2.2 million to a total of $3.6 million, paying a deferred termination fee of $3.85 million on or before January 4, 2027, and issuing 103,520 shares of common stock valued at approximately $0.5 million at $4.83 per share. Seres Therapeutics operates in the biotechnology industry, developing microbiome-based therapeutics.

At its reconvened 2026 Annual Meeting of Stockholders on July 8, 2026, Seres Therapeutics, Inc. stockholders approved an amendment and restatement of the 2025 Incentive Award Plan to increase the number of shares available for issuance under the plan by 900,000 shares. The meeting was reconvened from its original June 9, 2026, meeting due to a lack of quorum. Three Class II directors were elected, and PricewaterhouseCoopers LLP was ratified as the company's independent auditor. Seres Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for gut microbiome-related diseases.

Seres Therapeutics, Inc. announced top-line results from an Investigator-Sponsored Trial (IST) evaluating SER-155 in 15 patients with moderate-to-severe immune checkpoint inhibitor (ICI) induced gastrointestinal inflammation (irEC). At Day 15, 80% of participants (12 of 15) achieved an immunosuppressive-free clinical response, and 33% (5 of 15) achieved complete clinical remission. Results at Day 43 showed that 33% of participants maintained an immunosuppressive-free clinical response. The company is a biotechnology company focused on developing therapeutic interventions for gastrointestinal and inflammatory and immune-related bowel diseases.